

Supplementary Table 1. Studies Included in the Population Pharmacokinetic Analysis

Study Number	ClinicalTrials.gov Registration	Clinical Trial Phase	Participants or Type of Cancer	Participants, n	Pharmacokinetic Observations, n	Trial Name; Primary Reference
100483	NA	1	Healthy volunteers	24	332	Relative bioavailability, data on file (internal report #MRR 1653)
100484	NA	1	Healthy volunteers	15	206	Food effect study, data on file (internal report #MRR 1650)
10874	NCT00044512	2	HCC	28	194	Abou-Alfa et al ¹
11515	NCT00661375	2	RCC	98	151	Naito S, et al ²
11559	NCT00586105	2	RCC	39	328	
14295	NCT00984282	3	DTC	156	156	DECISION; Brose M, et al ³
100554	NCT00105443	3	HCC	190	335	SHARP; Llovet J, et al ⁴
11849	NCT00492752	3	HCC	29	229	Asia Pacific; Cheng AL, et al ⁵
11213	NCT00073307	3	RCC	195	363	TARGET; Escudier B, et al ⁶
14898	NCT01098760	4	HCC	85	847	HATT; Lin S, et al ⁷

DTC=differentiated thyroid cancer; HCC=hepatocellular carcinoma; NA=not applicable; RCC=renal cell carcinoma.

1. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. *J Clin Oncol.* 2006;24:4293-4300.
2. Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. *BJU Int.* 2011;108:1813-1819.

3. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. *Lancet*. 2014;384:319-328.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008;359:378-390.
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol*. 2009;10:25-34.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med*. 2007;356:125-134.
7. Lin SM, Lu SN, Chen PT, et al. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. *Hepatol Int*. 2017;11:199-208.